Categories: News

NeoGenomics to Present at 18th Annual Needham & Company Health Care Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

FT. MYERS, FLORIDA / ACCESSWIRE / April 2, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Sharon Virag, Chief Financial Officer, and Bill Bonello, Chief Strategy and Corporate Development Officer, Director of Investor Relations, will be presenting at the 18th Annual Needham & Company Health Care Conference on Tuesday, Apr. 9, 2019 at 4:10pm ET in New York, NY.

The presentation will be webcast live and accessible online via the investors section of the Company’s website, www.neogenomics.com. A replay of the webcast will be archived for 90 days following the presentation.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe. For additional information about NeoGenomics, visit http://neogenomics.com/.

Forward Looking Statements

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including the information set forth in the “Full-Year 2019 Financial Outlook”. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of the Company’s ability to continue gaining new customers, offer new types of tests, integrate its acquisition of the Genoptix business, and otherwise implement its business plan, as well as additional factors discussed under the heading “Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K filed with the SEC on February 26, 2019. As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. In addition, it is the Company’s practice to make information about the Company available by posting copies of its Company Overview Presentation from time to time on the Investor Relations section of its website at http://ir.neogenomics.com/.

Forward-looking statements represent the Company’s estimates only as of the date such statements are made (unless another date is indicated) and should not be relied upon as representing the Company’s estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its estimates change.

For further information, please contact:

NeoGenomics, Inc.
William
Bonello
Chief Strategy and Corporate Development Officer
Director, Investor Relations
(239) 690-4238 (w) (239) 284-4314 (m)
bill.bonello@neogenomics.com

SOURCE: NeoGenomics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/540866/NeoGenomics-to-Present-at-18th-Annual-Needham-Company-Health-Care-Conference

user

Recent Posts

Smartee Unveils ‘Live Update’ to Slash Treatment Planning Time from Days to Seconds

SHANGHAI, June 30, 2025 /PRNewswire/ -- In an era where real-time treatment agility defines competitive…

2 hours ago

Enhancing Mobility and Independence: VARON Oxygen Concentrators Deliver a New Standard of Freedom and Care

NEW YORK, June 30, 2025 /PRNewswire/ -- For individuals managing respiratory conditions, every breath matters—and…

2 hours ago

XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations

CAMBRIDGE, Mass., June 29, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in…

8 hours ago

Medical Device Contract Manufacturing Market to Reach $171.19 Billion by 2032, Growing at a CAGR of 9.9% from 2025, Says Meticulous Research®

Market Growth Driven by Outsourcing Preferences, Advanced Manufacturing Technologies, Regulatory Compliance Expertise, and Industry 4.0…

14 hours ago

Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select…

23 hours ago